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Abstract
Anti-Sm antibodies are highly specific markers for the diagnosis
of systemic lupus erythematosus (SLE). This specificity suggests
that the immunoregulation of these autoantibodies would reflect
fundamental immune abnormalities in this disorder. As a clue
to this immunoregulation, we have investigated the isotype
distribution of anti-Sm antibodies by enzyme-linked immuno-
sorbent assays. We have found that the anti-Sm response is
markedly restricted to the IgGl heavy chain isotype. On the
other hand, the light chain distribution reflects that in normal
serum, while isoelectric focusing analysis fails to show an
oligoclonal pattern. The related specificity, anti-ribonucleopro-
tein, is also restricted to IgGl, while the SLE-specific antibody
anti-double-stranded DNA is mostly IgGl with a lesser con-
tribution by IgG3. These results suggest that antinuclear
antibodies that are strongly associated with SLE are produced
by a T cell-dependent response, probably driven by antigen.
The immunoregulation of the response to several autoantigens
may be quite similar.
Introduction
Systemic lupus erythematosus (SLE)' is characterized by the
production of a spectrum of autoantibodies that includes a
large, but finite, number of different specificities (1). The
extensive variety of these abnormal antibodies implies the
action of general immunoregulatory deficits. Many immuno-
logical abnormalities have been described in SLE, but it is not
clear how any of these relate to autoantibody production (2).
In general, it has been difficult to study the autoantibody
responses themselves (3).
Certain autoantibodies are highly specific for the diagnosis
of SLE. These include anti-Sm, directed at a small nuclear
ribonuclear protein particle (4, 5), and anti-double-stranded
DNA (6). Anti-Sm antibodies probably do not play a critical
role in the pathogenesis of the clinical manifestations of SLE,
while anti-DNA antibodies are almost certainly important in
the development of nephritis in many patients (7). Nevertheless,
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the diagnostic specificity of both of these antibodies strongly
implies that their production is intimately linked with the
basic immunoregulatory abnormalities that cause SLE. In
addition, the fact that both these antibodies are relatively
specific for murine SLE further underlines their fundamental
importance (8, 9).
In the current work, we present a detailed study of the
isotype distribution and heterogeneity of anti-Sm antibodies
in human SLE sera. The rationale for this work is based on
the assumption that the character of a serological response will
reflect in vivo immunoregulation of that response. Work with
a variety of exogenous antigens in animals has already indicated
that certain isotypes are "T-dependent" and others are "T-
independent" (10-14). In human studies, protein antigens
which would be T-dependent in animals have tended to elicit
IgGl and IgG3 responses, while T-independent antigens elicit
IgG2 responses (15-17). IgG4 responses have mainly been
seen in sera from patients hypersensitized to allergens (18-21)
and in hemophiliacs with anti-factor VIII (22) or anti-factor
IX (23). Furthermore, in animals, IgG responses tend to be
more T cell-dependent than IgM responses. In mice we have
already found that the anti-Sm response is skewed toward the
T cell-dependent IgG2a subclass (24). Separate work by our-
selves and others have demonstrated a T cell dependence of
the MRL disease in general (25), as well as a T cell requirement
for the anti-Sm response in particular (26, 27).
In the present report, we also examine the clonality of the
anti-Sm response as a further clue to its immunoregulation.
The potential mechanisms one could evoke to explain the
escape of a single clone of autoantibody-producing cells are
different from what would be required to explain a polyclonal
response. We have found evidence for polyclonality of the
anti-Sm response, in spite of its striking subclass restriction.
Finally, we have compared the isotype distribution of other
antibody responses in the anti-Sm sera examined, and we have
examined the subclass distribution of the related specificity,
anti-nuclear ribonucleoprotein (RNP) and another SLE-specific
antibody, anti-double-stranded DNA (ds DNA).
Methods
Sera. 42 anti-Sm-positive sera were identified by double immunodif-
fusion using standard references (28). The sera were among those
submitted to the clinical laboratory for routine antinuclear antibody
testing. All patients (except one with diffuse interstitial pulmonary
fibrosis) with anti-Sm antibody had the clinical diagnosis of SLE
(including overlaps), although this was not a criterion for their inclusion.
Sera had been stored at -200C prior to use. During the course of the
current studies, they were held at 40C with 0.1% sodium azide.
Antigens for enzyme-linked immunosorbent assays (ELISA). Sm
antigen was affinity purified from RNAse- and DNAse-digested rabbit
thymus extract as previously described (29). It was free of RNP, SSA,
and SS-B, as determined by double immunodiffusion. It showed
polypeptide bands of 15,000 and 17,000 mol wt. RNP antigen was
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affinity purified in a parallel manner, except that it was not digested
with nucleases. Pneumococcal polysaccharides were in the form of
Pneumovax (Merck, Sharp and Dohme, West Point, PA) and were
used at 10 ug/ml. Trinitrophenylated bovine serum albumin (TNP-
BSA) was made by conjugating trinitrobenzene sulfonate with BSA.
The resultant product had a molar ratio (TNP/BSA) of 16. It was
utilized in the ELISA assay at 10 Ag/ml. Tetanus toxoid was obtained
as a purified preparation from the Massachusetts Department of Public
Health (Boston, MA) and was used at a concentration of I ug/ml.
Streptococcal cell wall was prepared as previously described (30) and
used at a concentration of 10 ;ig/ml.
Isotype reagents and isotype-specific proteins. Myeloma proteins,
purified by preparative electrophoresis as previously described ( 15, 31),
were used for isolation of polyclonal isotype reagents, testing their
specificity, determining standard curves, and as solid-phase reagents
for further absorptions as necessary. The proteins were all >99% pure,
as determined by double-antibody radioimmune assay (32). Polyclonal
anti-isotype antisera were produced in rabbits or in monkeys. For anti-
IgA, anti-IgD, anti-IgE, and anti-IgM, rabbits were immunized with
myeloma proteins. Resulting antisera were absorbed with solid-phase
gels of IgG myelomas of both light chain types and then affinity-
purified on gels of the appropriate isotype. Anti-IgGl and anti-IgG3
antibodies were produced in rabbits that were previously tolerized to
IgGs of the other subclasses (33). Anti-IgG2 and anti-IgG4 reagents
were produced in monkeys immunized with isolated heavy chains.
The specific antibodies were absorbed and affinity-purified in a manner
similar to that described for the anticlass reagents. In all cases, the
purifications were monitored by double immunodiffusion using purified
myeloma proteins. In spite of specificities shown by this technique for
each reagent, further absorptions were necessary for the ELISA assays,
as described below. Anti-light chain antisera were produced in rabbits.
Goat anti-F(ab')2 was obtained from a goat immunized with polyclonal
human IgG and was affinity-purified on the pepsin F(ab')2 fragments
of polyclonal human IgG.
Monoclonal antisubclass reagents were the kind gift of Dr. Charles
Reimer (Immunological Products Branch, Center for Disease Control,
Atlanta, GA). The following clones were used: 6012 (originally from
Dr. R. Jefferis, Birmingham, England [34]), anti-IgGl; 6014, anti-
IgG2; 6051, anti-IgG3; and 6022, anti-IgG4. The specificity of these
clones was confirmed with standard curve assays utilizing appropriate
and inappropriate myeloma proteins, either directly bound to microtiter
plates or bound by anti-light chain reagents. Each of the clones showed
no significant cross-reactivity, except 6012, which in some situations
recognized IgG3 at -5% the level of IgGl, and IgG2 and IgG4 at
<1%. The monoclonal antibodies were all obtained as lyophilized
ascitic fluids and were reconstituted in 0.5% BSA with 0.1% azide.
ELISA assays. Specific antibodies and their isotypes were detected
in ELISA assays, which were modifications of a previously described
technique (24). Sm or other antigens were added to polyvinyl chloride
microtiter plates (Dynatech Laboratories, Inc., Alexandria, VA) in 0.2
M borate-buffered saline, pH 8.4, with five protease inhibitors (0.5
mM paramethylsulfonyl fluoride, 10 mM EDTA acid, 50 mM E-
aminoocaproic acid, 1 mM o-phenanthroline, and 10 mM benzamidine
[Sigma Chemical Co., St. Louis, MO]) (BBS-PI). After 5-h incubation
at 4°C, the plates were washed and were nonspecifically coated with
BBS-PI plus 0.5% BSA and 0.4% Tween 80. In the IgG subclass assays,
0.1% normal goat serum was also added to the coating buffer to
decrease background. After 1 h at 4°C, the plates were aspirated and
samples were added in coating buffer. Each sample was tested at three
dilutions for every isotype. The appropriate dilutions (that fell in the
linear portion of the standard curves) were determined empirically in
preliminary assays with each serum and ranged from 10-3_10-5. The
plates were incubated overnight at 4°C. They were washed again on
the following day, and affinity-purified anti-isotype biotinylated reagents
were added for a further incubation at 4°C for 3 h. The concentrations
of the anti-isotype reagents used were determined empirically in
preliminary experiments to give approximate comparable optical den-
sities (ODs). After this incubation, the plates were again washed, and
avidin-alkaline phosphatase was added in coating buffer for a further
3-h incubation. The plates were then again washed, and the substrate
paranitrophenylphosphate was added at a concentration of 1 mg/ml
in 0.01 M diethanolamine, pH 9.8. The development of OD45 was
followed at appropriate intervals with a Dynatech microELISA auto-
reader (MR580; Dynatech Laboratories).
The assays with monoclonal antibodies were performed in a similar
manner, up to the second day of assay. At that time, the monoclonals
were added in diluting buffer. The dilutions utilized were determined
in preliminary experiments to give comparable ODs when tested
against myeloma proteins that had been coated directly onto microtiter
plates: 6012, 1:25,000; 6014, 1:7500; 6051, 1:10,000; and 6022,
1:40,000. The plates were incubated for 2 h at 4VC, washed, and then
a 1:1000 dilution of affinity-purified biotinylated rabbit anti-mouse
IgG was added for a further 2-h incubation at 4VC. After further
washing, avidin-alkaline phosphatase at a dilution of 1:500 was added
for 2 h at 4VC. The plates were then washed again, and substrate was
added for color development as described above.
It should be emphasized that appropriate absorptions were critical
to the performance of the ELISA assays described. For example, the
reagents used in the first step of the standard curve assays with the
polyclonal antisera had to be absorbed against IgG from rabbits and
monkeys to prevent direct binding to the polyclonal anti-isotype sera.
In addition, each biotinylated polyclonal anti-isotype antibody had to
be absorbed with inappropriate isotype myeloma proteins in solid
phase. The exact absorptions were determined in extensive preliminary
assays using graded amounts of gels of each specificity. The rabbit
anti-mouse IgG used to develop the monoclonal antibody assays was
absorbed with human IgG. In addition, all polyclonal reagents were
absorbed with antigens tested in a given assay.
A critical aspect for the interpretation of the isotype assays was the
ability to compare them quantitatively. With the polyclonal anti-
isotype reagents, this was accomplished by constructing standard curves
for each isotype. For IgA, IgD, IgM, IgE, and IgD, the standard curve
ELISA was performed by initially coating the plates with 1 gg/ml of
affinity-purified rabbit anti-human X-chains. Then, in place of serum
samples, graded dilutions of M-light chain myelomas of the appropriate
heavy chain were added. The assays were developed as described
above, and standard curves were constructed after subtracting the
appropriate controls. The ODs obtained for each serum for each
isotype were referred to these standard curves in order to yield an
estimate in micrograms per milliliter of anti-Sm antibody of that
isotype. For the IgG subclass assays, the initial coating step was a goat
anti-human F(ab')2, which had mainly anti-K-chain specificity. For the
standard curve, dilutions of K chain myelomas of the appropriate IgG
subclasses were utilized. For the light-chain assays, standard curves
were constructed by using affinity-purified anti-IgGl antibodies as the
first step, and IgGl myelomas of K- and M-light chains in graded
amounts.
With the monoclonal antibody assays, it was not feasible to
construct such standard curves. Therefore, the reagents were initially
standardized by measuring binding to microtiter plates coated with
graded amounts of myeloma proteins. Equivalent binding of the
myeloma proteins to the microtiter plates was assured by simultaneous
assays with a monoclonal anti-IgG reagent which did not have subclass
selectivity. Appropriate dilutions were chosen to insure that each of
the four subclass assays gave comparble ODs.
Anti-RNP antibodies. The monoclonal antibodies were utilized in
a similar set of assays to determine the IgG subclass distribution of
anti-nRNP antibodies. Since the RNP preparation was inevitably
contaminated with Sm determinants, all sera in this assay were
simultaneously tested against Sm. The increased reactivity of sera
typed as anti-RNP with the RNP antigen compared with the Sm
antigen indicated that the assay preferentially measured anti-RNP
rather than anti-Sm antibodies. Sera typed as anti-Sm-positive, anti-
RNP-negative in the same assays showed much higher reactivity with
Sm as compared with RNP.
Anti-DNA antibodies. Anti-ds DNA antibodies were measured by
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a standard Crithidia lucilia assay using commercial slides (Kallestad
Laboratories, Inc., Austin, TX). The sera were tested at neat, 1:4,
1:10, and then at serial two-fold dilutions. The assays were developed
with fluorescein-conjugated IgG fractions of anti-isotype sera, which
were purified by absorptions as described (35). Each IgG was used at
a concentration fourfold less than the lowest concentration that gave
a visible immunoprecipitin line against an appropriate myeloma protein.
C3 fixation test by Crithidia was done as previously described (36).
Isoelectric focusing of anti-Sm antibodies. Isoelectric focusing was
performed in 1% agarose (IsoGel; Marine Colloids, Rockland, ME)
with 2% ampholytes, pH 3.5-9.5 (Marine Colloids). The gels were
focused for 10 min at constant power of 1 W, then for 30 min with
constant power of 10 W. The adequacy of focusing of each run was
monitored with easily visualized standard proteins, including horse
myoglobin, sperm whale myoglobin, cytochrome C, and ferritin (Sigma
Chemical Co., St. Louis, MO). Complete focusing was further assured
by adding a strong anti-Sm serum in both the acidic and alkaline
ranges and determining that the final banding patterns were comparable.
Sera to be tested were dialyzed against ampholytes and added by a
filter paper strip near the expected acidic portion of the gel. When the
focusing was complete, the pH gradient was read by microelectrode,
and the proteins were precipitated in 18% sodium sulfate for 1 h at
room temperature. Precipitated bands were fixed with 0.5% glutaral-
dehyde in 18% sodium sulfate for 1 h at room temperature, followed
by sodium borohydride at 10 gg/ml for 2 h at room temperature. The
fixed gels were then washed overnight. The following day, they were
overlaid with a cellulose acetate sheet impregnated with 100 Ag/ml of
purified Sm conjugated to biotin. After further washing, the gels were
exposed to avidin conjugated with horseradish peroxidase, followed by






















Specificity of the anti-Sm ELISA assay. In preliminary inves-
tigations, we determined the antigen specificity of our anti-Sm
ELISA assay. The antigen utilized was highly purified, and
was the same preparations used in our murine anti-Sm ELISA
assays (24). In a survey of human sera, only immunodiffusion
positive anti-Sm sera gave strong positivity in the ELISA assay
(Fig. 1). Some patients with weaker immunodiffusion lines did
not give consistent ELISA positivity, and a single patient with
SLE that was immunodiffusion-negative gave significant ELISA
results.
We also utilized an extensive series of controls to assure
the isotype specificity of each assay. All affinity-purified anti-
isotype reagents had to be absorbed further for use in the
ELISA assay. Their specificity in the ELISA was then guaranteed
by testing of the isotype reagent against all other isotypes in
the standard curve assay, and in the anti-Sm assay itself, by
inhibiting positivity for each isotype preferentially with the
appropriate isotype. With the monoclonal reagents, the speci-
ficities were guaranteed by testing in standard curves.
Isotype analysis ofanti-Sm antibodies. 19 anti-Sm-positive
SLE sera gave strong enough results in the ELISA assay for
isotype analysis. The overall isotype distributions are compiled
in Table I. In every case, the most prominent isotype was
IgG1. In many sera, particularly those with high anti-Sm
values, over 90% of the antibody was of the IgG1 isotype. In
fact, as shown in Fig. 2, there was a direct correlation between
the level of IgG 1 anti-Sm and the fraction of the antibody that
was of this isotype (r = 0.85).
All sera also had IgG3 and IgM anti-Sm antibodies detect-
able. Some sera had IgA, IgG2, or IgG4 antibodies present,
Figure 1. Specificity of anti-Sm ELISA for immunodiffusion-positive
anti-Sm sera. 42 anti-Sm-positive, 42 anti-Sm-negative SLE, 29 rheu-
matoid factor (RF)-positive, and 11 normal sera were tested at a 10-4
dilution for IgGl anti-Sm antibodies.
usually in very low amounts. No IgD or IgE anti-Sm antibodies
were seen above the limits of detectability (0.2 and 0.02 ,ug/
ml, respectively).
Several points emerge from these data. First of all, in every
case, the anti-Sm response was mostly IgG. In particular, the
IgGl isotype was represented far out of proportion to its
expected concentration in total serum IgG (37, 38). Table I
presents the mean isotype concentration for the 19 sera
examined. By this analysis, IgGl represents 96% of the total
population's anti-Sm antibody or 98% of the population's IgG
anti-Sm. If a geometric mean is determined for each isotype,
then IgG1 is found to represent 91% of the total population
anti-Sm or 95% of IgG anti-Sm. Finally, if the percentage of
each isotype of anti-Sm is determined for each serum separately
and then these percentages are averaged, then IgG1 is found
to represent an average of 79% of total serum anti-Sm or 87%
of IgG anti-Sm.
In an additional series of experiments, we determined the
light chain distribution of anti-Sm antibodies in these same
sera. The results, shown in Fig. 3, indicate that in every case,
except one weakly reactive serum, both K- and X-chains were
detectable. In most sera, the K-chains were somewhat more
prominent than the X-chains and the overall geometric means
of K-anti-Sm and X-anti-Sm were 101 and 55, respectively.
This light chain distribution is quite similar to the expected
distribution of light chains in serum IgG.
Further validation of the IgG subclass assays. Although
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Table I. Isotype Distribution ofHuman Anti-Sm Antibody*
Patient IgM IgD IgG4 IgG2 IgG3 IgG I IgE IgA
1 11 <0.2 4 <10 16 15,000 <0.02 <0.4
2 16 <0.2 1 <10 15 1,700 <0.02 <0.4
3 9 <0.2 42 85 32 5,900 <0.02 3
4 11 <0.2 0.1 11 1 1,500 <0.02 <0.4
5 17 <0.2 <0.1 <10 0.4 700 <0.02 1
6 100 <0.2 0.1 11 3 570 <0.02 8
7 6 <0.2 0.1 <10 0.7 190 <0.02 0.8
8 6 <0.2 0.1 52 2 380 <0.02 17
9 40 <0.2 0.8 <10 0.8 480 <0.02 <0.4
10 14 <0.2 0.2 <10 105 510 <0.02 <0.4
11 5 <0.2 <0.1 <10 29 190 <0.02 4
12 14 <0.2 <0.1 <10 13 16 <0.02 <0.4
13 78 <0.2 <0.1 <10 28 123 <0.02 4
14 53 <0.2 <0.1 <10 19 80 <0.02 2
15 27 <0.2 <0.1 <10 45 60 <0.02 <0.4
16 42 <0.2 <0.1 <10 21 155 <0.02 <0.4
17 23 <0.2 <0.1 <10 6 1,300 <0.02 0.6
18 17 <0.2 <0.1 <10 26 190 <0.02 2
19 11 <0.2 <0.1 <10 37 210 <0.02 1
X 26 <0.2 2.6 16 20 1,540 <0.02 3.3
SEM 6.0 2.2 4.4 5.7 808 - 1.2
Percent of total 1.6 <0.01 0.16 1.0 1.2 96 <0.001 0.2
* Values given in micrograms per milliliter.
every isotype anti-Sm assay was performed simultaneously
with a standard curve that had been previously checked for
specificity and reliability, it remained possible that the marked
skewing of the anti-Sm response to the IgGl isotype could be
an artifact due to a systematic error introduced by our meth-
odology. In order to rule out this possibility, we utilized a set
of murine monoclonal antibodies with specificities of the
human IgG subclasses. Due to the peculiarities of the mono-
clonal reagent and their limited supply, we could not develop
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Figure 2. Correlation of serum lgG I anti-Sm levels and subclass
restriction. The horizontal axis depicts the absolute amount of IgG I
anti-Sm. The vertical axis shows this quantity divided by the total
serum anti-Sm as determined by summing the absolute quantities of
each separate isotype.
at predetermined dilutions that were found to be relatively
equipotent in detection of myeloma proteins in ELISA assays.
The results of a typical experiment are summarized in Fig. 4.








Figure 3. Light chain distribution of anti-Sm antibodies. Absolute
amounts of anti-Sm antibodies of the K- and X-isotopes were deter-
mined as described. K- and A-determinations for an individual patient
are connected by a straight line. Also shown is the geometric mean
levels of the K- and A-anti-Sm antibodies.
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Figure 4. IgG subclass distribution of anti-Sm and other antibodies
determined with hybridoma reagents. ELISA assays for the indicated
antigen specificities were developed with standardized IgG subclass
specific monoclonal antibodies. For each serum, the sum of the ODs
obtained in all four assays was divided into the results with each
monoclonal to determine the percent contribution of each subclass to
the total response. The bars indicate the mean percents for each
subclass for all sera. Seven individual anti-Sm sera are shown and
correspond to those listed in Table I: o, patient 1; A, patient 14; v,
patient 8; D, patient 2; ., patient 5; A, patient 17; v, patient 3; 0,
normal human serum. Points < 3% were omitted from the graph for
clarity. All sera were tested in all assays, except that the results of the
normal serum in the anti-Sm assay did not give sufficient OD for
analysis. Antigens utilized: Sm; TNP-BSA; tetanus toxoid (Tet. tox.);
Pneumovax (pneumococcal polysaccharides (Pneumo.); group A
streptococcal cell wall (Strep.).
the anti-Sm response appeared to be markedly skewed to the
IgG1 isotype. In contrast, pneumococcal polysaccharide anti-
bodies in these same sera were mainly IgG2 and IgGl, while
anti-TNP and anti-group A streptococcal cell wall were of
several isotypes. Tetanus toxoid antibodies in these sera were
mainly IgGl, as has been previously reported (16). As none of
these assays showed significant IgG4 antibodies, we performed
an additional control with 12 hyperimmune antiragweed sera
(provided by Dr. David Klapper, University of North Carolina,
Chapel Hill, NC) in a ragweed-specific ELISA and 7 hyper-
immune antihouse dust mite sera (provided by Dr. Thomas
Platts-Mill, University of Virginia, Charlottesville, VA) in a
mite-specific ELISA. In one antiragweed serum and one anti-
mite serum, the specific antibodies were mainly IgG4, as
determined with the monoclonal reagents. Although this assay
could not be done with the anti-Sm SLE sera, it did confirm
that the monoclonal IgG4 reagent would bind to appropriate
antibodies in an ELISA assay similar to the anti-Sm assay.
Isoelectric focusing analysis of anti-Sm antibodies. The
light chain distribution of anti-Sm antibodies, as determined
by the ELISA technique, suggested that these antibodies were
polyclonal, in spite of their subclass restriction. We further
analyzed this issue by focusing anti-Sm sera in agarose gels
and overlaying the patterns with biotinylated Sm antigen.
Positive staining was obtained with 10 of the stronger anti-Sm
sera. Multiple anti-Sm negative SLE and normal sera gave no
visible staining. Although in some cases anti-Sm bands were
present, in all patterns the anti-Sm activity included diffuse
staining ranging from an isoelectric point of pH 6 to pH 9.5
(Fig. 5). These patterns were consistent with the involvement
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Figure 5. Isoelectric focusing analysis of the heterogeneity of anti-Sm
antibodies. Anti-Sm-positive sera (lanes B, C, and D corresponding to
patients 1, 3, and 8 from Table I) and normal human serum (lane E)
were focused in agarose gels and overlain with Sm antigen in an
enzyme technique. Lane A contains myoglobin and cytochrome C
standards, while lane F contains ferritin.
IgG subclass ofanti-RNP antibodies. Anti-RNP antibodies
are related to anti-Sm antibodies because the two specificities
are frequently associated in SLE patients and because the
antigenic determinants for each specificity are complexed
together in nRNP particles (39, 40). We would therefore
predict that the immunoregulation of anti-RNP and anti-Sm
specificities would be similar and that anti-RNP antibodies
should also be restricted to the IgG1 subclass. To test this
hypothesis, we used the monoclonal antibodies to determine
the IgG subclass distribution of nine sera typed as anti-RNP-
positive, anti-Sm-negative by double immunodiffusion. The
anti-RNP sera selected showed much higher reactivity with
the RNP preparation than they did with (RNAse-digested) Sm
(Table II). The IgG subclass distribution of the anti-RNP
antibodies was similar to what we had found with anti-Sm
antibodies, in that the IgG1 isotype accounted for >90% of
the reactivity.
Isotype ofanti-DNA antibodies. In a final set of experiments,
we determined the isotype distribution of anti-DNA antibodies
by the Crithidia lucilia assay. The polyclonal isotype reagents
were utilized at a dilution four times greater than their
endpoint titer, as determined by immunodiffusion. The results
are shown in Table III. In accord with previous work by others
(41, 42), the anti-DNA response was generally restricted to
IgM and the IgGl and IgG3 isotypes. In most cases, the titer
with the IgG1 reagent was higher than with the IgG3 reagent.
Occasional sera had IgG4, IgG2, or even IgE anti-DNA
antibodies. Specificity for each isotype was checked by inhibition
with appropriate myeloma proteins. Light chain analysis in-
dicated the presence of both K- and X-anti-DNA antibodies in
the great majority of sera. Complement fixation by the Crithidia
assay was also determined on these same sera and was found
not to correlate with any obvious aspects of the isotype
distribution.
Discussion
We have determined that the anti-Sm autoantibodies in sera
of patients with SLE were relatively restricted to the IgGl
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Table IL IgG Subclass Distribution ofAnti-RNP Antibodies
Percent of total OD Total OD for four subclasses
Patient Diagnosis IgG I IgG2 IgG3 IgG4 2(ODRWp) (ODs.)
1 PSS/DM 95 4 1 0 1.420 0.136
2 SLE 74 3 1 21 0.775 0.063
3 PSS 97 2 1 1 1.143 0.039
4 PSS/DM 93 2 4 0 0.461 0.044
5 MCTD 86 12 2 0 0.367 0.087
6 SLE 98 1 1 0 0.627 0.446
7 SLE 94 4 1 0 1.063 0.599
8 MCTD 96 1 2 1 0.353 0.131
9 Cervical dysplasia 92 1 2 4 0.752 0.305
X 92±8 3±3 2±1 3±7 0.773±0.371 0.206±0.200
Abbreviations used in this table: DM, dermatomyositis; MCTD, mixed connective tissue disease; PSS, progressive systemic sclerosis.
isotype. In spite of this subclass restriction, these antibodies isotype detection was monitored by initial preliminary studies
were polyclonal, as judged by the presence of both K- and X- with standard curves of inappropriate myelomas. In addition,
light chains and by the diffuse patterns on isoelectric focusing. the actual anti-Sm and anti-DNA tests were further controlled
The related specificity anti-RNP was also nearly entirely IgGl. by showing that only the appropriate myeloma would inhibit
Anti-DNA antibodies were mainly of the IgM, IgG 1, and IgG3 the assay positivity. To rule out further any possibility of
isotypes, and like the anti-Sm antibodies, contained both K- systematic errors, the IgG subclass distribution was confirmed
and X-light chains. using monoclonal reagents, which showed the same striking
An essential aspect of studies of this sort is an assurance predominance of the IgG 1 subclass in the anti-Sm response,
of specificity of the assays employed and the avoidance of while other responses had different subclass distributions
systematic methodological idiosyncrasies which would skew (Fig. 5).
the results toward a particular isotype. The specificity of The subclass distribution of human autoantibodies has
Table III. Ig Isotypes in Human Systemic Lupus Erythematosus ds DNA
Antibodies as Determined by Indirect Immunofluorescence Using Crithidia Luciliae (liter/titer)
Patient Polyvalent IgM IgD IgG4 IgG2 IgG3 IgG I IgE IgA K X C3 fixation
Ba 2,560 640 40 160 - 640 640 8
McK 1,280 320 - 20 4 20 80 - 320 320 128
Th 1,280 320 80 640 - 320 640
Va 1,280 10 40 320 80 160 ND
Gr 640 160 80 160 320 640 512
He 640 10 4 40 10 - 20 20
Mu 640 80 20 80 40 - 80 80 32
Gi 640 80 - 4 10 - - 80
Ed 512 640 40 320 - 80 160
Ra 320 4 10 4 20 4
Hal 320 4 - 10 80 80 80
Br 320 4 - 4 4 80
Fi 320 80 80
Har 320 640 - 40 80 320
Wi 320 40 80 640 - 320 320 ND
Pe 160 20 20 20 - 40 20
Br 160 20 4 40 40
Mo 160 40 -
Les 160 4 1 40 - 80 80 ND
McP 80 4 4 4 - 4 4 ND
Oa 80 40 - 4
Pe 80 - - 4 80
Ph 40 10 -
Al 40 80 - 1 10 4 40 10 2
Lea 40 4 - 10 4 4 4 4
McD 20 80
ND, not determined.
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been examined by several investigators previously. Sontheimer
and Gilliam (41) found that anti-DNA antibodies are mainly
of the IgG 1 and IgG3 subclass, in accord with our results.
Zouali et al. (42) also confirmed the distribution of anti-DNA
antibodies. However, they reported that anti-RNP antibodies
were of the IgG2 subclass, in contrast to our finding of an
IgGl restriction similar to that of anti-Sm. Antinuclear anti-
bodies detected by immunofluorescence have been characterized
as unrestricted (35, 43), or as mainly IgGl (44) or IgGl and
IgG3 (45). Antithyroglobulin has been found to be unrestricted
(46), while the acetylcholine receptor antibodies in certain
myasthenic patients were restricted to the IgG3 subclass (47).
In our studies of anti-La (anti-SS-B) antibodies, we have found
that they are mainly of the IgGl subclass, in accord with our
results with anti-Sm (Pearce, D. C., W. J. Yount, and R. A.
Eisenberg, submitted for publication). Finally, in our earlier
work with the anti-Sm response in mice, we found a relative
restriction to the IgG2a subclass (24).
The isotype restriction and polyclonality of the anti-Sm
response suggests certain conclusions regarding their production
in vivo. First, since the anti-Sm, anti-RNP, anti-La, and ainti-
DNA responses are all relatively restricted to the same T cell-
dependent isotype (IgGl), it is probable that T cells play an
important role in the production of these antibodies in vivo
and their immunoregulation may be similar. Second, the
polyclonality of the anti-Sm response, like that of the anti-La
response, suggests that it is not the result of a small number
of mutations creating "forbidden clones" (48). Rather, it is
more probable that the response is antigen-driven. This is
consistent with interpretations based on the antigen specificity
of these responses (49, 50). The current work is also consistent
with previous studies which showed that anti-Sm was mainly
IgG and could fix complement (51).
The present results may also explain the old observation
of restricted electrophotetic mobility of anti-Sm antibodies
(28). This is probably due to their subclass restriction, rather
than to oligoclonality. In addition, the relatively normal dis-
tribution of K- and M-light chains in the anti-Sm response
indicates than neither chain is uniquely essential for the anti-
Sm specificity. This is in distinction to the rheumatoid factor
response, which either in monoclonal rheumatoid factors or
in the polyclonal response, is relatively K restricted (52).
At this point, it is essential to further define the heterogeneity
and specificity of the anti-Sm response. This is complicated
by the fact that the Sm antigen contains multiple polypeptides,
although our preparation may be somewhat simpler (29, 50).
Therefore, it is possible that certain populations of anti-Sm
antibodies may see one peptide in favor of another. We have
recently developed a polyclonal anti-idiotypic reagent which
identifies a cross-reactive idiotype(s) in anti-Sm antibodies
from some of the same sera tested in the present report (53).
Future investigations will involve the definition of anti-Sm
idiotypes by these reagents, as well as with monoclonal reagents,
and the determination of the relationship of these idiotypes to
specificity of anti-Sm antibodies for different Sm polypeptides.
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